Study for clinical efficacy of Ivabradine in convalescent patients with acute myocardial infarction

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019625

Enrollment

Unknown

Registered

2018-11-20

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

control group:BetalocZOK

experimental group:Ivabradine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. More than 18 years old; 2. Initial acute ST-segment elevation myocardial infarction for 1-2 weeks, emergency or elective PCI operation; 3. Killip grade I-III; 4. Sinus rhythm; 5. Low-dose betaloc sustained-release tablets (23.75mg qd) have been accepted for at least 1 week, Resting heart rate =75bpm measured by 12-lead ECG.

Exclusion criteria

Exclusion criteria: 1. Ivabradine was treated within 2 weeks; 2. Cardiogenic shock; 3. Mechanical complications after myocardial infarction; 4. Sick sinus syndrome or sinus block; 5. Third degree atrioventricular block; 6. Severe hypotension (<90/50mmHg); 7. Severe liver dysfunction (Child-Pugh score = 10 points); 8. End stage of renal failure (Creatinine clearance <15ml/min); 9. Pregnant, lactating women and women of childbearing age who have not taken appropriate contraceptive measures 10. Patients who cannot participate in the visit as planned.

Design outcomes

Primary

Measure	Time frame
heart rate;Blood pressure;	—

Countries

China

Contacts

Public ContactChengzhi Lu

Department of Cardiology, Tianjin First Central Hospital

lucz8@126.com+86 13512967656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026